Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) was the target of a large growth in short interest in October. As of October 13th, there was short interest totalling 3,183,085 shares, a growth of 53.3% from the September 29th total of 2,076,679 shares. Based on an average daily volume of 2,062,293 shares, the days-to-cover ratio is currently 1.5 days. Approximately 13.8% of the company’s stock are sold short.

A hedge fund recently raised its stake in Marinus Pharmaceuticals stock. KCG Holdings Inc. boosted its stake in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) by 29.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 64,539 shares of the biopharmaceutical company’s stock after acquiring an additional 14,692 shares during the period. KCG Holdings Inc. owned 0.30% of Marinus Pharmaceuticals worth $114,000 at the end of the most recent reporting period. 23.60% of the stock is owned by hedge funds and other institutional investors.

Marinus Pharmaceuticals (NASDAQ MRNS) opened at 5.29 on Friday. Marinus Pharmaceuticals has a 52-week low of $0.82 and a 52-week high of $8.22. The company has a 50 day moving average of $5.13 and a 200-day moving average of $2.58. The stock’s market capitalization is $137.94 million.

Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.06. Equities research analysts anticipate that Marinus Pharmaceuticals will post ($0.74) EPS for the current year.

A number of research firms recently commented on MRNS. ValuEngine downgraded shares of Marinus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, July 7th. JMP Securities reaffirmed an “outperform” rating and issued a $11.00 target price (up from $5.00) on shares of Marinus Pharmaceuticals in a research report on Tuesday, September 12th.

COPYRIGHT VIOLATION NOTICE: “Marinus Pharmaceuticals, Inc. (MRNS) Short Interest Up 53.3% in October” was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.

Receive News & Ratings for Marinus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.